AVVAA announces financial loss, promises turn around

The loss was reported at $1,419,377, or $0.02 per share, a figure that compares to a loss of $799,056 or $0.02 for the three months ending August 2005.

However, AVVVA, which specializes in natural and therapeutic skin products, has stated that it intends to surge ahead with large scale advertising and marketing campaigns in order to regain some brand awareness and in the hope of being able to report a profit in the future.

CEO and chairman of the company, Jack Farley, said: "we have a number of substantial developments in the recent quarter that should result in success for our products in the marketplace."​

He also said that the company is hoping to benefit from existing campaigns and that it is planning to implement 'a number of planned initiatives to ensure long term success'.

It was also stated that the sale team had forged many new in-roads, and had targeted the existing pet and equine products that are sold in Canada and America.

The company's flagship skin care range is hoped to be essential in aiding the revenue turnaround. The skin care range is manufactured to target common skin ailments such as eczema, psoriasis and acne, and is scientifically registered and FDA-Compliant.

AVVAA is also planning to manufacture and launch a new skin care line, OTC Neuroskin, across US and the global market through major mass food and drug channels.

Shareholders of the company will, however, not be kept in the dark regarding the progress of the company with Jack Farley stating that: 'our plan is to issue a shareholder letter in the very near future to update shareholders more specifically on the progress of the company'.